D70.4 is a billable diagnosis for other specified neutropenia, a hematologic disorder characterized by an absolute neutrophil count (ANC) significantly lower than the standard reference range, typically below 1,500 cells per microliter. This specific classification excludes congenital agranulocytosis, drug-induced variants, and neutropenia resulting from acute infections. It primarily encompasses cyclic (periodic) neutropenia, a rare condition often caused by mutations in the ELANE gene, where neutrophil levels fluctuate in a predictable 21-day cycle. It also covers neutropenia associated with specific metabolic defects like glycogen storage disease type Ib or rare immune-mediated pathways. Patients with this condition are at a significantly increased risk for bacterial and fungal infections due to the impaired innate immune response. Clinical management often involves monitoring for febrile episodes and the therapeutic use of Granulocyte Colony-Stimulating Factor (G-CSF) to elevate the ANC during periods of severe depletion.
Distinguish between specified and unspecified neutropenia by documenting the underlying etiology and chronicity. For D70.4, clearly state if the condition is chronic idiopathic neutropenia or another specified form that does not meet the criteria for cyclic, drug-induced, or congenital types.
Example: Patient is a 45-year-old female with a 12-month history of persistent absolute neutrophil count (ANC) ranging from 800 to 1100 cells/microL. Bone marrow aspirate and biopsy performed on 01/15/2025 showed normal cellularity with no evidence of dysplasia or maturation arrest. Genetic testing for ELANE and HAX1 was negative. Diagnosis is chronic idiopathic neutropenia (D70.4). Patient remains asymptomatic without recurrent infections. Management includes semi-annual CBC monitoring and strict febrile precautions.
Billing Focus: Documentation of the ANC value and the duration (exceeding 3 months) supports the specific diagnosis of chronic idiopathic neutropenia over transient or unspecified leukopenia.
Document the absence of causative medications to support D70.4 and rule out D70.1. A clear statement that the neutropenia is not secondary to chemotherapy or other drugs is vital for accurate code selection.
Example: Absolute neutrophil count today is 950 cells/microL. Reviewed current medication list including Lisinopril and Metformin; neither is associated with the patient's long-term neutropenia. History is negative for recent cytotoxic therapy. The neutropenia is specified as idiopathic and non-drug induced, meeting criteria for D70.4.
Billing Focus: Explicitly ruling out drug-induced causes prevents incorrect assignment of D70.1 and ensures the most specific code is used for the idiopathic manifestation.
Specify the severity of neutropenia using ANC thresholds. While the ICD-10 code D70.4 does not vary by severity, the clinical documentation of mild, moderate, or severe status supports Medical Decision Making complexity.
Example: Follow-up for chronic specified neutropenia. Current ANC is 450 cells/microL, indicating severe neutropenia (ANC less than 500). Patient is currently afebrile and lacks oral ulcers. Plan: Start prophylactic Levofloxacin and schedule STAT follow-up if temperature exceeds 100.4 F.
Billing Focus: Documenting ANC thresholds and resulting prophylactic measures justifies higher level E/M codes such as 99214 due to moderate to high risk of complications.
Include results of specialized hematologic testing such as bone marrow biopsy or flow cytometry in the assessment to justify the use of a specified neutropenia code.
Example: Hematology consult for persistent neutropenia. Flow cytometry shows no aberrant immunophenotype. Bone marrow biopsy confirms other specified neutropenia (idiopathic) with no evidence of myelodysplastic syndrome. This confirms D70.4 and excludes D46.9.
Billing Focus: Linking diagnostic test results directly to the D70.4 diagnosis provides the clinical gold standard for specificity during payer audits.
Document any associated symptoms or complications, such as stomatitis, gingivitis, or recurrent skin infections, to demonstrate the clinical impact of the neutropenia.
Example: Patient with known chronic specified neutropenia (D70.4) presents with recurrent aphthous stomatitis and painful gingival inflammation. ANC today is 1100. Symptoms are likely related to the underlying neutropenia. Prescribed chlorhexidine rinses and scheduled follow-up with dentistry.
Billing Focus: Documenting manifestations of the neutropenia supports the necessity of frequent office visits and more complex management plans.
Used for routine monitoring of stable neutropenia with low risk and straightforward management.
Appropriate when the patient has symptomatic neutropenia or requires medication adjustments like G-CSF.
Common for the initial consultation of a patient referred for an unexplained low neutrophil count.
The primary laboratory test used to identify and monitor the absolute neutrophil count for D70.4.
Essential for evaluating neutrophil morphology to rule out dysplasia or other hematologic disorders.
The definitive procedure to rule out bone marrow failure or malignancy in chronic neutropenia.
Used for the administration of Filgrastim (G-CSF) in the clinical setting.
A basic component of the monitoring process for patients with chronic neutropenia.
Used in the workup to exclude lymphoma or leukemia as a cause for low neutrophils.
Used when a patient with severe neutropenia presents with acute febrile illness requiring urgent management.